Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

Roche's Perjeta pertuzumab

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer

Bristol-Myers Squibb (BMS) building

BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

Rounds off a week of deals in the immunotherapy space for big pharma

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

- PMLiVE

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

- PMLiVE

Keytruda cleared for melanoma in Europe

Merck’s new PD-1 drug will compete against rival BMS for market share

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

NHS sponsors charity on metastatic breast cancer study

Breast Cancer Now to study tissue shortly after death

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links